The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1047
ISSUE 1047
February 26, 1999
Issue 1047
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Infliximab (Remicade) for Crohn's Disease
February 26, 1999 (Issue: 1047)
Infliximab, a monoclonal antibody that inhibits tumor necrosis factor, has received an accelerated approval from the FDA for intravenous treatment of moderate to severe Crohn's disease refractory to other medical treatment.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.